CL2025002377A1 - Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo - Google Patents

Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo

Info

Publication number
CL2025002377A1
CL2025002377A1 CL2025002377A CL2025002377A CL2025002377A1 CL 2025002377 A1 CL2025002377 A1 CL 2025002377A1 CL 2025002377 A CL2025002377 A CL 2025002377A CL 2025002377 A CL2025002377 A CL 2025002377A CL 2025002377 A1 CL2025002377 A1 CL 2025002377A1
Authority
CL
Chile
Prior art keywords
polymorph
protein kinase
inhibitor
preparation
mek protein
Prior art date
Application number
CL2025002377A
Other languages
English (en)
Inventor
Tian Hongqi
HUANG Gongchao
Original Assignee
Shanghai Kechow Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Kechow Pharma Inc filed Critical Shanghai Kechow Pharma Inc
Publication of CL2025002377A1 publication Critical patent/CL2025002377A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a un polimorfo de un compuesto de benzotiazol como un inhibidor de la proteína quinasa Mek, a un método de preparación del mismo y a un uso medicinal del mismo.
CL2025002377A 2023-02-10 2025-08-08 Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo CL2025002377A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310099716 2023-02-10
CN202410090964 2024-01-22

Publications (1)

Publication Number Publication Date
CL2025002377A1 true CL2025002377A1 (es) 2025-12-19

Family

ID=92262078

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002377A CL2025002377A1 (es) 2023-02-10 2025-08-08 Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo

Country Status (11)

Country Link
EP (1) EP4663631A1 (es)
JP (1) JP2026505452A (es)
KR (1) KR20250153212A (es)
CN (1) CN120112519A (es)
AU (1) AU2024216900A1 (es)
CL (1) CL2025002377A1 (es)
CO (1) CO2025012210A2 (es)
MX (1) MX2025009373A (es)
PE (1) PE20260035A1 (es)
TW (1) TW202448867A (es)
WO (1) WO2024165044A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242163A1 (zh) * 2024-05-23 2025-11-27 上海科州药物股份有限公司 蛋白激酶mek抑制剂的盐及其用途
WO2025261499A1 (zh) * 2024-06-20 2025-12-26 上海科州药物股份有限公司 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103204822B (zh) * 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CN104119332B (zh) * 2014-07-08 2019-03-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途
CN105315293A (zh) * 2014-07-29 2016-02-10 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途
EP3860717A1 (en) * 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020198125A1 (en) * 2019-03-22 2020-10-01 Icahn School Of Medicine At Mount Sinai Methods for treating colorectal cancer
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法

Also Published As

Publication number Publication date
CN120112519A (zh) 2025-06-06
KR20250153212A (ko) 2025-10-24
AU2024216900A1 (en) 2025-09-25
TW202448867A (zh) 2024-12-16
JP2026505452A (ja) 2026-02-13
WO2024165044A9 (zh) 2025-07-03
PE20260035A1 (es) 2026-01-09
CO2025012210A2 (es) 2025-09-18
EP4663631A1 (en) 2025-12-17
WO2024165044A1 (zh) 2024-08-15
MX2025009373A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
CO2025012210A2 (es) Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
BR112021023457A2 (pt) Composto, uso do composto, composição, e, métodos para preparar a composição e um composto
CL2022000110A1 (es) Inhibidores de parp1
PH12021500014A1 (en) Fused ring compounds
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
CO2022000751A2 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
BR112021017049A2 (pt) Derivados de tiazol como inibidores de secreção de proteínas
MX2022004937A (es) Inhibidores de las cinasas raf.
EA202193015A1 (ru) Ингибиторы cdk
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
BR112022003357A2 (pt) Compostos heterocíclicos
MX388606B (es) Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX393879B (es) Métodos de preparación de niraparib.
CO2021003805A2 (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112019025028A2 (pt) Método para preparar um composto.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
BR112022002222A2 (pt) Derivados de quinolina como inibidores de proteínas quinases
MX2019013816A (es) Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos.
CO2022009068A2 (es) Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.